Abstract
For patients with recurrent, locally advanced or metastatic HNSCC, standard therapeutic options are limited and survival is dismal. AT-101 is a pan BCL-2 inhibitor with demonstrated anti-tumor activity, and may represent a promising new anticancer agent with a novel molecular mechanism of action. This phase 2 trial evaluated the efficacy and safety of AT-101 in combination with docetaxel as palliative treatment for patients with recurrent, locally advanced or metastatic HNSCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
